<DOC>
	<DOCNO>NCT00049244</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness combine BMS-247550 capecitabine treat patient metastatic breast cancer respond previous chemotherapy taxane anthracycline .</brief_summary>
	<brief_title>BMS-247550 Plus Capecitabine Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose BMS-247550 capecitabine , 2 different schedule , patient metastatic breast cancer previously treat taxane anthracycline . - Determine safety profile regimen patient . - Determine , preliminarily , antitumor activity regimen patient . OUTLINE : This dose-escalation study . Patients assign 1 2 group . - Group I : Patients receive BMS-247550 IV 3 hour day 1 oral capecitabine twice daily day 1-14 . - Group II : Patients receive BMS-247550 IV 1 hour day 1-3 capecitabine group I . Treatment group repeat every 3 week 2-18 course absence disease progression unacceptable toxicity . Cohorts 6 patient receive escalate dos BMS-247550 capecitabine maximum tolerate dose ( MTD ) determine group . The MTD define dose 1 6 patient experience dose-limiting toxicity . Additional patient treat MTD . Patients follow least 30 day every 3 month thereafter . PROJECTED ACCRUAL : Approximately 34-60 patient accrue study within 8-12 month .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm breast cancer Metastatic disease radiography histology Must receive prior chemotherapy taxane anthracycline adjuvant metastatic set No 2 prior chemotherapy regimen metastatic set Measurable evaluable disease Bone lesions measurable Primary breast lesion measurable assessed physical exam No active brain metastasis No cerebral edema CT scan MRI No progression since prior image study No requirement steroids No clinical symptom brain metastasis Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age 18 Sex Not specify Menopausal status Not specify Performance status ECOG 01 Life expectancy At least 3 month Hematopoietic Absolute neutrophil count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 9.0 g/dL Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) ALT great 2.5 time ULN Renal Creatinine less 1.5 time ULN Cardiovascular No uncontrolled significant cardiovascular disease No myocardial infarction within past year No uncontrolled angina within past year No history congestive heart failure No history atrial ventricular arrhythmia No history second thirddegree heart block No uncontrolled hypertension Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception HIV negative No hypersensitivity Cremophor EL fluorouracil No prior intolerance fluoropyrimidines No serious uncontrolled medical disorder active infection would preclude study No dementia alter mental status would preclude study No grade 2 great neuropathy ( neuromotor neurosensory ) PRIOR CONCURRENT THERAPY : Biologic therapy See Chemotherapy Prior immunotherapy allow No concurrent trastuzumab ( Herceptin ) No concurrent immunotherapy Chemotherapy See Disease Characteristics At least 3 week since prior chemotherapy ( 6 week nitrosoureas , mitomycin , doxorubicin HCl liposome ) At least 2 year since prior highdose chemotherapy bone marrow transplantation peripheral blood stem cell support No prior epothilone , capecitabine , continuousinfusion fluorouracil No concurrent chemotherapy Endocrine therapy Prior hormonal therapy allow No concurrent hormonal therapy Concurrent hormone replacement therapy allow Radiotherapy At least 3 week since prior radiotherapy No prior radiotherapy 25 % bone marrow No concurrent therapeutic radiotherapy Surgery Not specify Other At least 3 week since prior investigational cytotoxic agent No concurrent warfarin therapeutic anticoagulation Lowdose warfarin allow implanted port indwell catheter No concurrent experimental anticancer medication No concurrent antitumor therapy Concurrent bisphosphonates palliation bone metastases allow initiated study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>recurrent breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
</DOC>